Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272

Benzinga · 3d ago
Leerink Partners analyst David Risinger maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $276 to $272.